BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.6%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$10.2B
AUM Growth
+$10.2B
(+8.4%)
Cap. Flow
+$197M
Cap. Flow
% of AUM
1.92%
Top 10 Holdings %
Top 10 Hldgs %
30.33%
Holding
228
New
12
Increased
78
Reduced
41
Closed
15
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$72M |
| 2 |
Tandem Diabetes Care
TNDM
|
$48M |
| 3 |
IQVIA
IQV
|
$42.6M |
| 4 |
Adaptive Biotechnologies
ADPT
|
$39.3M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$39M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$238M |
| 2 |
Moderna
MRNA
|
$62.9M |
| 3 |
Cigna
CI
|
$45.4M |
| 4 |
Bristol-Myers Squibb
BMY
|
$41.5M |
| 5 |
DaVita
DVA
|
$39.6M |
Sector Composition
| 1 | Healthcare | 96.41% |
| 2 | Industrials | 0.94% |
| 3 | Technology | 0.31% |
| 4 | Financials | 0.04% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Ascendis Pharma
ASND
$12.1B
| – | – |
-15,500
| Closed | -$2M |
|
227
Cardinal Health
CAH
$36B
| – | – |
-24,000
| Closed | -$1.46M |
|
228
CureVac
CVAC
$1.21B
| – | – |
-28,900
| Closed | -$2.64M |
|